GB0821839D0 - The use of metformin and compounds containing metformin in the treatment of diseases or conditions in patients with raised serum amyloid A - Google Patents

The use of metformin and compounds containing metformin in the treatment of diseases or conditions in patients with raised serum amyloid A

Info

Publication number
GB0821839D0
GB0821839D0 GBGB0821839.8A GB0821839A GB0821839D0 GB 0821839 D0 GB0821839 D0 GB 0821839D0 GB 0821839 A GB0821839 A GB 0821839A GB 0821839 D0 GB0821839 D0 GB 0821839D0
Authority
GB
United Kingdom
Prior art keywords
metformin
patients
diseases
treatment
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0821839.8A
Other versions
GB2465796A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RANDEVA HARPAL S
TAN BEE K
Original Assignee
RANDEVA HARPAL S
TAN BEE K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RANDEVA HARPAL S, TAN BEE K filed Critical RANDEVA HARPAL S
Priority to GB0821839A priority Critical patent/GB2465796A/en
Publication of GB0821839D0 publication Critical patent/GB0821839D0/en
Publication of GB2465796A publication Critical patent/GB2465796A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB0821839A 2008-12-01 2008-12-01 Metformin for the therapeutic use of conditions with raised serum amyloid A levels Withdrawn GB2465796A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0821839A GB2465796A (en) 2008-12-01 2008-12-01 Metformin for the therapeutic use of conditions with raised serum amyloid A levels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0821839A GB2465796A (en) 2008-12-01 2008-12-01 Metformin for the therapeutic use of conditions with raised serum amyloid A levels

Publications (2)

Publication Number Publication Date
GB0821839D0 true GB0821839D0 (en) 2009-01-07
GB2465796A GB2465796A (en) 2010-06-02

Family

ID=40262405

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0821839A Withdrawn GB2465796A (en) 2008-12-01 2008-12-01 Metformin for the therapeutic use of conditions with raised serum amyloid A levels

Country Status (1)

Country Link
GB (1) GB2465796A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113186275A (en) * 2021-06-16 2021-07-30 上海交通大学医学院附属仁济医院 Application of serum amyloid A1 in preparation of biomarker for diagnosing polycystic ovarian syndrome
CN113712962A (en) * 2021-09-30 2021-11-30 深圳市第三人民医院(深圳市肝病研究所) Application of troglitazone in anti-mycobacterium tuberculosis drugs

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095379A1 (en) * 2011-01-11 2012-07-19 Universität Basel Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
SG11201501719UA (en) * 2012-09-07 2015-04-29 Agency Science Tech & Res Methods to inhibit intracellular growth of bacteria and to treat bacteria-mediated diseases
WO2016192098A1 (en) * 2015-06-05 2016-12-08 台中荣民总医院 Pharmaceutical composition containing acarbose and use thereof in regulating immunization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543118A (en) * 1999-04-29 2002-12-17 シティ・オブ・ホープ Pentoxifylline, pioglitazone and metformin are inhibitors of the formation of advanced glycation end products (AGE)
WO2005046675A2 (en) * 2003-11-07 2005-05-26 Jordan Holtzman Methods for enhancing glutathione peroxidase activity
AU2005299808B2 (en) * 2004-10-25 2009-08-20 Novartis Ag Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin
JOP20180109A1 (en) * 2005-09-29 2019-01-30 Novartis Ag New Formulation
WO2008141074A1 (en) * 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113186275A (en) * 2021-06-16 2021-07-30 上海交通大学医学院附属仁济医院 Application of serum amyloid A1 in preparation of biomarker for diagnosing polycystic ovarian syndrome
CN113712962A (en) * 2021-09-30 2021-11-30 深圳市第三人民医院(深圳市肝病研究所) Application of troglitazone in anti-mycobacterium tuberculosis drugs

Also Published As

Publication number Publication date
GB2465796A (en) 2010-06-02

Similar Documents

Publication Publication Date Title
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
IL209887A0 (en) Treatment for diabetes in patients inappropriate for metformin therapy
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
EP1985302A4 (en) Medicament for treatment of tumor and the use thereof
HK1158705A1 (en) Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
IL219945A (en) Double-acylated glp-1 derivatives and their use in the manufacture of a medicament for treating diabetes
PL1912650T3 (en) Use of flibanserin in the treatment of obesity
PT2614832T (en) Diagnosis and treatment of preeclampsia
EP2182978A4 (en) Tissue kallikrein for the treatment of diseases associated with amyloid protein
PL2148667T3 (en) Use of cyclohexanehexol derivatives in the treatment of ocular diseases
ZA200806808B (en) Treatment of stressed patients
IL212672A (en) Cycloundecadepsipeptide compounds and use of said compounds in the manufacture of medicaments
HK1168283A1 (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1
GB0821839D0 (en) The use of metformin and compounds containing metformin in the treatment of diseases or conditions in patients with raised serum amyloid A
IL177609A (en) Use of gabaculine or its analog in the manufacture of a medicament for treating hepatocellular carcinoma
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
GB2458868B (en) Fluphenazine based combination for use in the treatment of protein aggregation diseases
IL211267A (en) Oxadiazole derivatives and medicaments and use thereof for the treatment of diabetes
ZA200807874B (en) Preventative treatment and remission of allergic diseases
HRP20151393T8 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
PL2160213T3 (en) Kit for the extracorporeal treatment of a biological fluid of a patient, and unit provided with said kit
EP2231163A4 (en) Compounds and therapeutic use thereof
PT2182954T (en) Use of nor-bile acids in the treatment of arteriosclerosis

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)